Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has shared an update.
On August 5, 2025, Smith & Nephew plc experienced a change in its voting rights structure due to an acquisition or disposal by BlackRock, Inc. The transaction resulted in BlackRock holding 6.76% of the total voting rights, up from a previous 6.61%. This adjustment in holdings could influence Smith & Nephew’s shareholder dynamics and potentially impact its strategic decisions moving forward.
The most recent analyst rating on (SNN) stock is a Hold with a $27.27 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats shows strong financial performance and positive earnings call sentiment, driving the overall score. Technical indicators suggest a strong upward trend, though the stock appears overbought. Valuation metrics indicate potential overvaluation, which slightly tempers the overall score.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based company operating in the medical technology industry. It specializes in the development and manufacturing of advanced medical devices, including orthopedics, wound management, and surgical devices, with a focus on enhancing patient outcomes and healthcare efficiency.
Average Trading Volume: 931,939
Technical Sentiment Signal: Buy
Current Market Cap: $15.56B
For an in-depth examination of SNN stock, go to TipRanks’ Overview page.